Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice4-Year Results From a Large 2-Institutional Cohort Study
Peter Wenaweser, MD*,
Joost Daemen, MD ,
Marcel Zwahlen, PhD ,
Ron van Domburg, PhD,
Peter Jüni, MD,
Sophia Vaina, MD, PhD,
Gerrit Hellige, MD*,
Keiichi Tsuchida, MD,
Cyrill Morger, MD*,
Eric Boersma, PhD,
Neville Kukreja, MBBS, MRCP,
Bernhard Meier, MD*,
Patrick W. Serruys, MD, PhD and
Stephan Windecker, MD*,*
* Department of Cardiology, University of Bern, Bern, Switzerland
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Status of Antiplatelet Treatment at Time of Definite Stent Thrombosis
Proportion of patients with early and late stent thrombosis treated with dual, single, or no antiplatelet therapy.
|
|
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Cumulative Incidence of Definite ST Stratification
(A) Cumulative incidence of definite stent thrombosis (ST) stratified by stent type. (B) Cumulative incidence of definite ST stratified by stent type and treatment site. PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent(s); SES = sirolimus-eluting stent(s).
|
|
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Cumulative Incidence of Ischemic Adverse Events in 8,146 Patients During 4 Years of Follow-Up
MI = myocardial infarction; PCI = percutaneous coronary intervention; ST = stent thrombosis.
|
|
|
